Xuxi Zhang

ACCORDION Eye Study $ , 2016 Glycemic control study Baseline and follow ‐ up (8 years): IG:658 CG:652 Patients with type 2 diabetes Female (%):36.5 Mean age: 61.4±5.9 Duration of diabetes (year): 9.6±6.7 HbA1c (%): 8.1±0.9 Blood pressure (mm Hg): Systolic: 132.7±16.1 Diastolic: 74.7±10.1 Total Cholesterol (mg/dl): LDL: 97.7±32.7 HDL: 41.9±11.0 BMI: 32.4±5.2 Without diabetic retinopathy (%): 53.2 Patients with type 2 diabetes Female (%):38.8 Mean age: 61.2±5.7 Duration of diabetes (year): 10.1±6.9 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Systolic: 133.4±16.7 Diastolic: 74.7±10.6 Total Cholesterol (mg/dl): LDL: 100.7±32.6 HDL: 41.4±10.3 BMI: 32.3±5.6 Without diabetic retinopathy (%): 51.7 RCT USA Canada Glycemic ‐ control intervention Intensive glycemic control (targeting HbA1c level of 6.0%) vs. Standard control (target of 7.0–7.9%) Blood pressure study Baseline and follow ‐ up (8 years): IG:280 CG:268 Patients with type 2 diabetes Female (%):45.4 Mean age: 61.3±5.8 Duration of diabetes (year): 10.5±6.8 HbA1c (%): 8.3±1.0 Blood pressure (mm Hg): Systolic: 136.8±15.9 Diastolic: 74.7±10.1 Total Cholesterol (mg/dl): LDL: 106.1±36.4 HDL: 46.2±12.5 BMI: 32.3±5.6 Without diabetic retinopathy (%): 51.1 Patients with type 2 diabetes Female (%):45.5 Mean age: 61.1±6.1 Duration of diabetes (year): 10.1±7.3 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Systolic: 138.6±15.9 Diastolic: 74.7±10.6 Total Cholesterol (mg/dl): LDL: 102.1±34.4 HDL: 45.9±12.8 BMI: 32.4±5.3 Without diabetic retinopathy (%): 50.0 RCT USA Canada Blood ‐ pressure ‐ control intervention Intensive blood pressure control (targeting systolic BP of 120mmHg) or standard treatment (140 mmHg) Lipid study Baseline and follow ‐ up (8 years): IG:399 CG:363 Patients with type 2 diabetes Female (%):27.6 Mean age: 61.8±5.8 Duration of diabetes (year): 9.8±6.5 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Patients with type 2 diabetes Female (%):36.9 Mean age: 61.1±5.6 Duration of diabetes (year): 9.4±6.6 HbA1c (%): 8.1±0.9 Blood pressure (mm Hg): RCT USA Canada Lipid ‐ control intervention Fenofibrate (160mg/day), to decrease triglyceride levels and to increase HDL cholesterol levels vs. Placebo 186 Chapter 7